BG101126A - The use of muramylpeptide compounds - Google Patents

The use of muramylpeptide compounds

Info

Publication number
BG101126A
BG101126A BG101126A BG10112697A BG101126A BG 101126 A BG101126 A BG 101126A BG 101126 A BG101126 A BG 101126A BG 10112697 A BG10112697 A BG 10112697A BG 101126 A BG101126 A BG 101126A
Authority
BG
Bulgaria
Prior art keywords
muramylpeptide
compounds
prophylaxy
treatment
isoglutam
Prior art date
Application number
BG101126A
Other languages
Bulgarian (bg)
Inventor
Philip Ledger
Original Assignee
Peptech (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech (Uk) Limited filed Critical Peptech (Uk) Limited
Publication of BG101126A publication Critical patent/BG101126A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The muramylpeptide compounds, and in particular N-acetyl-d-glucosaminyl-(1-4)-N-acetylmuramul-L-alanyl-D-isoglutam in (GMDP) are used for the treatment and prophylaxy of inflammatory dermatological conditions such as psoriasis and in the treatment and prophylaxy of immunodependent diseases of the skin and the mucuous membranes.
BG101126A 1994-07-11 1997-01-10 The use of muramylpeptide compounds BG101126A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9413935A GB9413935D0 (en) 1994-07-11 1994-07-11 Use of maramyl peptide compounds
CN95194573A CN1155245A (en) 1994-07-11 1995-07-10 Use of muramyl peptide compounds
PCT/GB1995/001619 WO1996001645A1 (en) 1994-07-11 1995-07-10 Use of muramyl peptide compounds

Publications (1)

Publication Number Publication Date
BG101126A true BG101126A (en) 1997-09-30

Family

ID=25743816

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101126A BG101126A (en) 1994-07-11 1997-01-10 The use of muramylpeptide compounds

Country Status (13)

Country Link
EP (1) EP0768888A1 (en)
JP (1) JPH10505580A (en)
CN (1) CN1155245A (en)
AU (1) AU2893595A (en)
BG (1) BG101126A (en)
CA (1) CA2194678A1 (en)
CZ (1) CZ4797A3 (en)
GB (1) GB9413935D0 (en)
HU (1) HUT77290A (en)
IL (1) IL114542A0 (en)
SK (1) SK2697A3 (en)
WO (1) WO1996001645A1 (en)
ZA (1) ZA955763B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7352498A (en) * 1997-04-11 1998-11-11 Kaluzhin, Oleg Vitalievich Immunomodulator and pharmaceutical compositions with antitumor properties, and afood additive
GB9710351D0 (en) * 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
AU4423799A (en) * 1998-06-04 1999-12-20 Cornell Research Foundation Inc. Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
DE10106852A1 (en) * 2001-02-14 2002-09-05 T Luger Anti-inflammatory compounds
FR2899466B1 (en) * 2006-04-07 2008-09-26 Oreal USE OF C-GLYCOSIDE COMPOUND ACTIVATING AGENT AND REGULATOR OF SKIN IMMUNITY
EP2094277A4 (en) 2006-10-20 2010-01-20 Kim Soo Youl A composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them
US8603978B2 (en) * 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
FR2933984B1 (en) * 2008-07-15 2013-01-04 Univ Bourgogne D, D MURAMYLDIPEPTIDE, DERIVATIVE COMPOUNDS AND USE FOR THE TREATMENT OF ATHEROMOUS PLAQUES
WO2016138286A1 (en) 2015-02-26 2016-09-01 Stc.Unm Irgm and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
US10927147B2 (en) 2015-12-10 2021-02-23 Bharat Biotech International Limited Muramyl peptide derivative compound, synthesis and uses thereof
US10576147B2 (en) 2015-12-15 2020-03-03 Bharat Biotech International Limited Muramyl peptide derivative compound, synthesis and uses thereof
BR112023018950A2 (en) 2021-03-19 2024-02-27 Icahn School Med Mount Sinai COMPOUND, NANOBIOLOGICAL AND PHARMACEUTICAL COMPOSITIONS, METHODS FOR TREATING A CELL PROLIFERATION DISORDER, FOR TREATING SEPSIS AND FOR ACTIVATING A NOD2 RECEPTOR, PROCESS FOR MANUFACTURING A NANOBIOLOGICAL COMPOSITION AND KIT

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357322A (en) * 1980-07-29 1982-11-02 Syntex (U.S.A.) Inc. Method of preventing, reducing or inhibiting inflammation
US4698330A (en) * 1983-06-27 1987-10-06 President & Fellows Of Harvard College Somnogenic compositions and method of use
HU205147B (en) * 1989-06-29 1992-03-30 Sandoz Ag Process for producing muramyl dipeptide derivative and pharmaceutical compostions comprising same
WO1993010148A1 (en) * 1991-11-19 1993-05-27 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock
GB9204354D0 (en) * 1992-02-28 1992-04-08 Biokine Tech Ltd Compounds for medicinal use
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
GB9326518D0 (en) * 1993-12-29 1994-03-02 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
CZ4797A3 (en) 1997-07-16
GB9413935D0 (en) 1994-08-31
HU9700071D0 (en) 1997-02-28
CN1155245A (en) 1997-07-23
JPH10505580A (en) 1998-06-02
AU2893595A (en) 1996-02-09
SK2697A3 (en) 1997-08-06
EP0768888A1 (en) 1997-04-23
WO1996001645A1 (en) 1996-01-25
IL114542A0 (en) 1995-11-27
HUT77290A (en) 1998-03-30
CA2194678A1 (en) 1996-01-25
ZA955763B (en) 1997-01-13

Similar Documents

Publication Publication Date Title
TR199901172T2 (en) Newly substituted pyrazole derivatives.
MX9700538A (en) Use of droloxifene for the treatment of cardiovascular diseases.
BG101284A (en) Compounds and methods for cancer treatment
AU6549898A (en) Method for the broad based treatment of infections, especially infections of organs such as the skin and vagina
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
BG104056A (en) Triazole compounds and their use as dopamine-d3-ligands
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
DE69905368D1 (en) Oxydiertes thymosin beta 4
AU5624699A (en) Use of 5ht-6 antagonists
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
BG101126A (en) The use of muramylpeptide compounds
DE60124715D1 (en) PRODUCTION OF BETA ENDORPHINE
HK1040983A1 (en) Quinones for treatment of diseases.
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
ES2190535T3 (en) LECTIN COMPOSITIONS AND USE OF THE SAME.
DK0700898T3 (en) L-carnitine salt and cosmetic and pharmaceutical preparations containing the same, for the treatment of dermatoses.
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
DK0700897T3 (en) L-carnitine salt and cosmetic and pharmaceutical preparations containing the same for the treatment of skin diseases
TR199900662T2 (en) The use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
TR200200278T2 (en) Calcilitic compositions
NO991734L (en) Pyrazolinones for the treatment of potency disorders
MXPA02003731A (en) Novel fusidic acid derivatives.
NO970185L (en) Use of (S) -adenosyl-L-methionine (SAMe) and its physiologically compatible salts for the treatment of reperfusion injury triggered by temporal-focal ischemia
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use